Economic Value Of Drugs Should Be Factor In FDA Approval, More Pharma Execs Say
This article was originally published in The Pink Sheet Daily
PwC Health Research Institute’s survey of 100 senior executives found 43% support FDA use of economic data in deciding whether to approve a drug, up from 14% four years ago.
You may also be interested in...
FDA-sponsor interactions vary widely, but more meetings still seem to speed applications; Special Protocol Assessments fall out of favor.
FDA may be wondering whether a lack of praise for its user fee program actually could be a criticism after a survey did not find overwhelmingly agreement the dollars were serving their intended purpose.
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.